For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | - | 0 | 0 | 0 |
| Research and development | 77,987,000 | 77,506,000 | 65,797,000 | 63,006,000 |
| General and administrative | 27,873,000 | 19,538,000 | 12,562,000 | 13,061,000 |
| Total operating expenses | 105,860,000 | 97,044,000 | 78,359,000 | 76,067,000 |
| Loss from operations | -105,860,000 | -97,044,000 | -78,359,000 | -76,067,000 |
| Other income, net | 13,299,000 | 8,133,000 | 4,425,000 | 4,940,000 |
| Total other income | 13,299,000 | 8,133,000 | 4,425,000 | 4,940,000 |
| Net loss | -92,561,000 | -88,911,000 | -73,934,000 | -71,127,000 |
| Basic EPS | -3.2 | -3.485 | -3.36 | -3.31 |
| Diluted EPS | -3.2 | -3.485 | -3.36 | -3.31 |
| Basic Average Shares | 28,883,596 | 25,510,775 | 21,977,268 | 21,474,827 |
| Diluted Average Shares | 28,883,596 | 25,510,775 | 21,977,268 | 21,474,827 |
Praxis Precision Medicines, Inc. (PRAX)
Praxis Precision Medicines, Inc. (PRAX)